Sun Pharma Expands Portfolio with ₹271 Crore Innovcare Acquisition Amid Strong Earnings Growth

Sun Pharmaceutical Industries Ltd ($SUNPHARMA) has announced the acquisition of 100% stake in Mumbai-based Innovcare Lifesciences Pvt. Ltd. for a cash consideration of approximately ₹271.2 crore, with the transaction expected to be completed on or before July 31, 2026. Innovcare operates in the pharmaceutical, nutraceutical and cosmeceutical segments, and the acquisition is aimed at strengthening Sun Pharma’s product portfolio and expanding its presence in high-growth healthcare categories. The company clarified that the deal is not a related-party transaction and that the promoter group has no interest in the target entity. On the financial front, Sun Pharma delivered a strong performance in Q4FY26, with net profit rising 26% year-on-year to ₹2,714 crore, broadly in line with market expectations of ₹2,742 crore. Revenue increased 12.8% to ₹14,612 crore from ₹12,959 crore a year ago and came slightly ahead of estimates of ₹14,528.1 crore. However, EBITDA margin contracted by 160 basis points to 27.1% from 28.7% in the previous year and remained below the expected 27.8%. The acquisition, combined with healthy earnings growth, reflects the company’s continued focus on strengthening its product offerings while maintaining growth momentum across its core business segments. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.